<DOC>
	<DOCNO>NCT00959686</DOCNO>
	<brief_summary>A Phase II clinical study determine efficacy single agent Bendamustine T cell lymphoma `` BENTLY '' .</brief_summary>
	<brief_title>Bendamustine Patients With Refractory Relapsed T-cell Lymphoma</brief_title>
	<detailed_description>The primary objective study define activity Bendamustine treatment T cell lymphomas . The activity Bendamustine determine response rate ( RR ) treatment within 22 day intravenous infusion enables get confidence interval 95 % probability overall response rate ( ORR ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients age 18 year . Refractory relapse peripheral Tcell NHL ( PTCL ) Cutaneous T cell lymphoma ( CTCL ) relapse refractory topical therapy ECOG score le 2 No major organ dysfunction unrelated lymphoma . Pregnant breast feed woman ECOG score &gt; 2 Estimate survival time &lt; 3 month Active infection severe organ dysfunction psychiatric condition unable patient receive chemotherapy Creatinine clearance &lt; 10 ml/min severe hepatic dysfunction relate lymphoma . Previous chemotherapy/immunotherapy within 3 week study entry Known seropositive active viral infection HIV , EBV , HCV CNS lymphoma Tcell Leukemia lymphoma associate HTLV1 Sezary syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bendamustine refractory relapse T-cell lymphoma .</keyword>
</DOC>